ArticlePharmacoEconomics2012

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Aurea Duran et al.PubMed ↗Publisher ↗

No numbers read from the abstract.